Clinical Trial Update: Dose Optimization Trial of CD19 Redirected Autologous T Cells [Phase 2]

View source ↗

Summary

Phase 2 dose optimization trial of CD19 redirected autologous T cells in adults with relapsed/refractory CLL or SLL has completed with posted results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Lymphocytic Leukemia
• Small Lymphocytic Lymphoma

Drugs mentioned

• CD19 Redirected Autologous T Cells

Snippet

Sponsor: University of Pennsylvania | Conditions: Adult Patients Who Have Relapsed or Refractory CLL (3rd Line) or SLL | Phase 2 | Status: COMPLETED | Results posted: 2019-02-26